Month: April 1999

Unilab Signs Agreement To Buy Bio-Cypher Labs

CEO SUMMARY: Unilab’s desire to purchase $60 million Bio-Cypher must be viewed against the impending acquisition by Quest Diagnostics of SmithKline Beecham Clinical Laboratories (SBCL). Whenever Quest takes control of SBCL’s lab operations, it automatically becomes a significant competitor to Unilab in the Golden State. For Unilab, acquiring Bio-Cypher represents both an offensive and defensive …

Unilab Signs Agreement To Buy Bio-Cypher Labs Read More »

“April 26, 1999 Intelligence: Late Breaking Lab News”

Think turnover among laboratory executives and administrators is high? Get a load of this! Among CEOs at the nation’s 4,838 general, non-federal acute-care hospitals, the turnover rate was 16.9% during 1998. This was up from 12.1% in 1997. It means that one of every six hospitals got a new CEO last year, and three of …

“April 26, 1999 Intelligence: Late Breaking Lab News” Read More »

Lab Contracts Priced Below Cost May be Defined as Inducement

PROBABLY THE MOST SERIOUS problem in the lab industry is one of its own making. “Below cost” contracting is a practice where clinical laboratories offer the managed care company a price which is less than its cost to provide the testing. With laboratory overcapacity still abundant in many cities, “below cost” contract pricing remains common. …

Lab Contracts Priced Below Cost May be Defined as Inducement Read More »

Legislators May Repeal NY Lab Surcharge Tax

CEO SUMMARY: After two years of concerted effort, laboratories in New York are optimistic that state legislators will finally repeal an 8.18% surcharge tax on clinical laboratory tests. The significant insight behind this story is how laboratories educated patients about the surcharge. The response was a public deluge of phone calls and letters to elected …

Legislators May Repeal NY Lab Surcharge Tax Read More »

Crises Management Plan Essential for Every Lab

CEO SUMMARY: “It can’t happen here” is not good management. All clinical laboratories and pathology practices should anticipate the worst and develop their own internal controls to prevent the unthinkable and prepare for the unexpected. Rogue phlebotomists like the one at SmithKline Beecham Clinical Laboratories can appear anywhere, with similar destructive consequences. WHAT’S HAPPENING TO …

Crises Management Plan Essential for Every Lab Read More »

Preparing for the Unexpected and Unimagined

WHO WOULD HAVE EVER PREDICTED THAT A PHLEBOTOMIST would reuse needles? Just as surprising, who would have ever predicted that the phlebotomist would be working at a respected clinical laboratory like SmithKline Beecham Clinical Laboratories (SBCL)? This shocking story is a reminder that laboratory executives should never forget to anticipate every potential problem, no matter how …

Preparing for the Unexpected and Unimagined Read More »

Labs Entering New Cycle Of Evolution and Change

CEO SUMMARY: As some of the nation’s most astute and forward-looking lab executives prepare to gather in New Orleans for the fourth annual EXECUTIVE WAR COLLEGE, it is time to share our assessment of the laboratory and pathology industry. Recent events presage another profound shift in trends driving the evolution of laboratory services. This shift …

Labs Entering New Cycle Of Evolution and Change Read More »

SBCL Phlebotomist Found Reusing Needles in Calif.

CEO SUMMARY: News that a phlebotomist employed by SmithKline Beecham Clinical Laboratories (SBCL) was discovered to be washing and reusing needles got national media attention last week. During her 22-month employment at SBCL, this phlebotomist apparently reused butterfly needles on “difficult to draw” patients. Ramifications of this discovery will affect not only SBCL, but the …

SBCL Phlebotomist Found Reusing Needles in Calif. Read More »

Client Service and Sales Fuel Fast Growth at AML

CEO SUMMARY: Here’s proof positive that effective management can make a positive difference in the financial performance of clinical labs. Upon taking title to American Medical Laboratories in the spring of 1997, its new owners used an emphasis on “customer-first” service and aggressive sales to transform the lab operation into a fast-growth revenue engine, doubling …

Client Service and Sales Fuel Fast Growth at AML Read More »

Neuromedical Systems Files Bankruptcy Action

CEO SUMMARY: Automated cytology technology suffered its first financial failure. Escalating losses and dismal revenue prospects combined to drive Neuromedical Systems, Inc. into bankruptcy. Its PapNet System for Pap smears was a pioneering technology that never achieved market acceptance. Neuromedical’s experience demonstrates that lab executives take a risk when they adopt new technology. Faced with …

Neuromedical Systems Files Bankruptcy Action Read More »